中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2015年
19期
16-18
,共3页
树突状细胞%细胞因子诱导的杀伤细胞%白细胞%红细胞%血小板%淋巴细胞
樹突狀細胞%細胞因子誘導的殺傷細胞%白細胞%紅細胞%血小闆%淋巴細胞
수돌상세포%세포인자유도적살상세포%백세포%홍세포%혈소판%림파세포
Dendritic cell%Cytokine induced killer cell%White blood cell%Red blood cell%Platelet%Lymphocyte
目的：探讨DC/CIK细胞治疗对白细胞、红细胞、血小板和淋巴细胞的影响。方法对接受DC/CIK细胞治疗的63例癌症患者的血细胞资料进行回顾性分析。结果在第一疗程DC/CIK细胞治疗前和第二疗程DC/CIK细胞治疗后，63例患者的WBC、RBC、PT和LYM的数量变化无统计学意义(P>0.05)。结论 DC/CIK细胞治疗几乎没有血液学毒副反应，临床应用安全。
目的：探討DC/CIK細胞治療對白細胞、紅細胞、血小闆和淋巴細胞的影響。方法對接受DC/CIK細胞治療的63例癌癥患者的血細胞資料進行迴顧性分析。結果在第一療程DC/CIK細胞治療前和第二療程DC/CIK細胞治療後，63例患者的WBC、RBC、PT和LYM的數量變化無統計學意義(P>0.05)。結論 DC/CIK細胞治療幾乎沒有血液學毒副反應，臨床應用安全。
목적：탐토DC/CIK세포치료대백세포、홍세포、혈소판화림파세포적영향。방법대접수DC/CIK세포치료적63례암증환자적혈세포자료진행회고성분석。결과재제일료정DC/CIK세포치료전화제이료정DC/CIK세포치료후，63례환자적WBC、RBC、PT화LYM적수량변화무통계학의의(P>0.05)。결론 DC/CIK세포치료궤호몰유혈액학독부반응，림상응용안전。
Objective To explore the impact of the DC/CIK(dendritic cell, DC/cytokine induced killer cell, CIK) cell therapy on white blood cell,red blood cell,platelet and lymphocyte. Methods A retrospective blood cell date analysis of 63 cases of cancer patients receiving DC/CIK cell therapy was done. Results The difference of the count of WBC,RBC,PT and LYM of 63 cancer patient was not statistically significant(P>0.05)before and after 2 cycles of DC/CIK cells infusion. Conclusions DC/CIK cell therapy has few hematology toxicity. Clinical use of DC/CIK cell therapy is safe.
